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Allelic loss on chromosome IOq in human lung cancer:
association with tumour progression and metastatic
phenotype
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Summary We analysed 78 carcinomas of the lung for allelic losses on chromosome 1Oq. The tumours were of different stage and grade and
comprised 22 small-cell lung carcinomas (SCLC), 40 squamous cell carcinomas (SCC), 11 adenocarcinomas, four large-cell carcinomas and
one carcinoid. They were investigated by six polymorphic markers located between 10q21 and 1Oqter. We observed a high incidence of loss
of heterozygosity (LOH) in SCLC (91%) and metastatic SCC (56%). Non-metastatic SCC showed deletions in three cases (14%) and no LOH
was found in the other types of non-small-cell lung cancer. The statistical analysis indicated that the presence of LOH correlated significantly
with advanced tumour stages in the entire collective and in particular within the SCLC and SCC subgroups. For SCC, a positive association
was found between LOH and metastases formation, while in SCLC the number of non-metastatic tumours was too small for a final conclusion.
Whereas SCLC was frequently characterized by multiple allelic losses, suggesting the deletion of the entire chromosomal arm, SCC showed
interstitial imbalances. A high incidence of allelic loss was observed between the markers D10S677 and D10S1223. The analysis of five
informative cases suggested the presence of two non-overlapping regions between the loci Dl0S677/D10S1237 and DlOS1213/DlOS1223.
In SCLC, we did not find mutations in the putative tumour-suppressor gene MXI1. The data indicate that LOH on chromosome 10q is
associated with tumour progression in SCC and SCLC. Thus it may become a useful genetic marker in the assessment of the malignant
potential of these tumour types.
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Cancer of the lung has the highest incidence of all solid tumours
and is the leading cause of cancer deaths (Pisani et al, 1993).
The major histopathological distinction of clinical relevance is
between small-cell and non-small-cell lung carcinomas. SCLC has
to be considered a systemic disease at the time ofdiagnosis as the
majority of cases show early metastases formation. It is preferen-
tially treated by chemotherapy and radiotherapy. The NSCLC
consist mainly of three subtypes, i.e. adenocarcinomas, squamous
cell carcinomas (SCC) and large-cell carcinomas (LCLC). The
significance of the latter group is unclear as LCLC frequently
show features ofeither adenocarcinomas or SCC; they can usually
be attributed to these two subgroups by ultrastructural examina-
tion. There is a prevailing pattern of distribution within the lung.
Whereas adenocarcinomas tend to be located in the periphery,
SCC and SCLC arise preferentially from the central bronchi near
the hilus.
A distinct histopathological diagnosis with far-reaching clinical
consequences, i.e. possibly curative operation vs palliative
chemotherapy, is often complicated by the morphological hetero-
geneity that occurs in up to 30% of cases (Muller and Fisseler-
Eckhoff, 1989). The tumourheterogeneity is reflected in the World
Health Organization (WHO) classification by the composite
entities such as combined oat cell carcinoma (SCLC with NSCLC
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component) and adenosquamous carcinoma (WHO, 1982).
Similar to the pattern of distribution, SCLC does coincide more
often with SCC than with adenocarcinoma (Hirsch et al, 1983). As
the morphological diagnosis may be biased by the tumour hetero-
geneity, additional criteria are necessary for the characterization of
lung carcinomas.
Genetic lesions form the basis oftumour initiation and progres-
sion. The assessment of allelic loss hinting at loci of putative
tumour-suppressor genes has proven valuable in the genetic char-
acterization oflung carcinomas (Tsuchiya et al, 1992; Gazdar et al,
1994; Sato et al, 1994; Thiberville et al, 1995; Neville et al, 1996).
We have shownpreviously that SCLC and a subset ofSCC is char-
acterized by DNA loss on chromosome lOq (Petersen et al, 1997a
and b; Schwendel et al, 1997). Allelotype studies in other tumour
types have suggested that chromosome lOq harbours at least one
gene that is important in the tumour progression of meningioma,
prostate cancer and brain tumours (von Deimling et al, 1992;
Rempel et al, 1993; Gray et al, 1995). As chromosome lOq loss
was the second most frequent finding in SCLC after 3p deletions,
which are implicated in early tumour development (Bockmuhl et
al, 1996; Califano et al, 1996), we speculated that this lesion may
contribute particularly to the highly malignantphenotype ofSCLC
and other types ofhuman lung carcinomas.
To test this hypothesis we investigated lung tumours of different
histological type, grade and stage for the presence ofallelic loss on
chromosome lOq. Six polymorphic markers at the loci D1OS677,
DIOS1237, DOS1213, DOS1223, DIOS169 and DlOS212 were
used to analyse paired samples of tumour and normal DNA of 78
lung cancerpatients. The collective was subdivided into fourgroups
that consisted of SCLCs, non-metastatic SCC, metastasizing SCC
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Table 1 Pathological data for the study cohort
Number of patients 78
Small-cell lung carcinomas 22
pMO 4
pM1 18
Squamous cell carcinomas (pM1)
G2
G3
Squamous cell carcinomas (pMO)
G2
G3
Other non-small-cell lung cancers
Large-cell carcinomas
Adenocarcinomas
Carcinoid
18
8
10
22
12
10
16
4
11
and other NSCLC. The results indicate that LOH on chromosome
lOq is significantly associated with advanced stages in SCLC as
well as tumourprogression and metastases formation in SCC. In the
othertypes ofNSCLC, exceptSCC, noLOH was detectable. Allelic
losses in SCLC generally extended over several genetic markers,
supporting our previous CGH results that the entire chromosomal
arm is usually affected by DNA loss. SCC more frequently showed
interstitial imbalances.
In addition, we investigated the SCLCs for mutations in the
helix-loop-helix and leucine-zipper exons of the MXI1 gene,
which negatively interacts with the myc protooncogene and has
been suggested as a tumour-suppressor gene (Eagle et al, 1995).
No mutations were detectable, indicating that a yet unknown
tumour suppressor gene on the distal chromosome lOq is involved
in lung carcinogenesis.
MATERIALS AND METHODS
Tumour samples
The pathological characteristics of the 78 tumour specimens
analysed are listed in Table 1. They were grouped according to
different pathological entities. The NSCLC were subdivided into
three groups, i.e. SCC without metastasis formation (pMO) at the
time of surgery, SCC with pathological evidence of a haemato-
geneous metastases (pMl) and the subgroup of 'otherNSCLC' that
consisted mainly ofadenocarcinomas and large-cell carcinomas. In
the group ofSCLC, all tumours except one showed either nodal or
haematogeneous metastases. All SCLC andmetastatic SCC tumour
specimens were derived from autopsies, whereas the other tumour
samples were generally obtained from surgical resections at the
Department of Surgery of the University Hospital Charite. In all
biopsy cases, the primary tumour was investigated.
Tumour and normal tissue were frozen in liquid nitrogen. DNA
was extracted from several 30-im cryostat tissue sections by
proteinase K digestion and phenol-chloroform extraction. The
tumour tissue was verified to consist ofaminimum of70% tumour
cells in each case. The tumour diagnosis and the histomorpho-
logical grading was based on the WHO criteria that were applied
to formalin-fixed, paraffin-embedded tissue sections that were
routinely stained by haematoxylin-eosin and periodic acid Schiff
(WHO, 1982). SCLC were classified as poorly differentiated
carcinomas (G3) for the statistical analysis of the tumour grade.
The pTNM and UICC stage were defined according to the
established criteria (International Union Against Cancer, 1982;
Mountain et al, 1991).
LOH analysis
Paired samples of tumour and normal DNA were assessed for
allelic losses by microsatellite polymorphism analysis. Sixdifferent
markers on chromosome lOq, i.e. DlOS169 (het. 0.73), D1OS677
(het. 0.81), DIOS1213 (het. 0.8), DlOS1223 (het. 0.74), DlOS1237
(het. 0.73) and DIOS212 (het. 0.71), were selected from the human
genome marker screening set (Dubovsky et al, 1995); the cytoge-
netic localization and the relative genetic distances are shown in
Figure 1. Primer sequences were obtained from the genome data-
base and commercially synthesized (MWG-Biotech, Ebersberg,
Germany). Polymerase chain reaction (PCR) was performed with
approximately 100 ng of DNA, 20 pmol of each primer and
200 gmol dNTPs. The DNA samples were denatured for 5 min and
then amplifiedby 35 cycles (1 minat95°C, 30s at 550C and 30s at
720C), followed by a final extension step of 5 min at 72°C. The
annealing temperature was modified for the marker DIOS1213 and
DIOS169 to 600C and for D1OS677 to 50°C. PCR products were
checked on 1.5% agarose gels andthen separatedby 5% denaturing
polyacrylamide gel electrophoresis (7M urea/TBE). The DNA frag-
ments werefinally visualized by non-radioactive detection as previ-
ously described (Petersen et al, 1996).
SSCP analysis
For mutational analysis ofthe MXI1 gene, the helix-loop-helix and
the leucine-zipper exons were amplified (Eagle et al, 1995). PCR
conditions were modified (10 x buffer with magnesium chloride,
300ng of template, 50pmol each primer, 200lmol dNTPs,
annealing temperature 60°C). Aliquots ofthese PCRfragments were
denatured and electrophoresed on a 5% non-denaturing polyacryl-
amide gel and detected non-radioactively (Petersen etal, 1996).
Sequencing
PCR products were purified from a 1.5% agarose gel and
sequenced by the dideoxy method using the Thermo Sequenase
(Amersham, Buckinghamshire, UK) and an automated DNA
sequencer (Licor-system purchased by MWG-Biotech).
Statistical analysis
Chi-square (x2) test was performed using the statistical software
package NCSS supplied by Unisoft (Augsburg, Germany).
RESULTS
LOH analysis
Representative allelotype data from three cases are shown in Figure
1. Patient no. 13 died from a SCLC whereas patients 28 and 39
suffered from a metastatic SCC. The results ofthe genetic analysis
together with the individual clinicopathological parameters of all
British JournalofCancer(1998) 77(2), 270-276 0CancerResearch Campaign 1998loq
11
/4
21
_ (D1OS109)
17
- D10S677
17
- DlOS1237
16
_ D1OS1213
6
D10S1223
12
DlOS169
9
D10S212
Case 13
T N
Case 28
_W .. Case 39
T N
cM
Figure 1 Localization of the investigated markers and examples of LOH analysis of three patients. Typically, the SCLC (case 13) showed allelic loss of multiple
markers, indicating that a substantial part of the chromosome was lost, whereas metastatic SCC (cases 28 and 39) carried more frequently interstitial allelic
imbalances. Cases 28 and 39 were used to define the minimal region of deletion located centromerically between the marker Dl0S677 and DlOS1237
cases are represented in Table 2. LOH was particularly prevalent in
SCLC carrying deletions in 20 out of 22 cases (91%). One of the
two cases without LOH was a SCLC that showed no evidence for
metastases formation, i.e. case no. 1. The second highest incidence
was observed in the subgroup of SCC with metastasis formation,
which harboured allelic loss in 10 of 18 cases (56%). Six of
these were poorly differentiated carcinomas (G3) and three were
moderately differentiated (G2). The SCC without haematogeneous
metastases (pMO) showed LOH in 3 of22 cases (14%), all ofwhich
were G3 tumours. No allelic loss was observed in the subgroup of
the other NSCLC. Overall 28 of 39 pMl tumours (72%) carried
LOH in contrast to 6 of39 non-metastatic (15%) tumours.
Seven cases showed interstitial allelic loss, i.e. cases 7, 23, 28,
29, 32, 39 and 43, suggesting two non-overlapping regions of
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Table 2 Survey of the genetic analysis and the clinicopathological data of individual cases
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Table 3 P-valuesa for correlations between LOH on chromosome 1Oq and clinicopathological parameters
pT pN+ pM1 UICC Grade
SCC 0.0197 0.0027 0.0049 0.0181 0.0324
SCLC 0.3300 0.0030 0.2211 0.0143
All tumours 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0002
aAccording toX2 test
LOH. One region was located centromerically between the
markers D1OS677 and DIOS1237 and was indicated by the cases
7, 28 and 39. The second was located telomerically between
DIOS1213 and D1OS1223 and was defined by cases 28 and 43.
The percentage ofinformative cases varied between 55% and 71%
for the selected markers.
Statistical analysis
The X2 test indicated that the presence of LOH on chromosome
10q correlated significantly with clinicopathological parameters
of tumour progression (Table 3). In particular, the association
between positive lymph node status (pN+) and advanced UICC
stage was highly significant in the entire tumour collective as well
as the subgroups of SCLC and SCC. There was no significant
correlation between the presence of LOH and either chemo-
therapy, radiotherapy or both regimens.
Mutational analysis
The SCLC tumour samples were furtherinvestigated formutations
in the MXIl gene. No mutations were found using either single-
strand conformation polymorphism (SSCP) analysis or direct
sequencing ofthe helix-loop-helix and leucine-zipper exons (data
not shown).
DISCUSSION
This study presents evidence that allelic loss on chromosome 10q
is significantly associated with advanced stages in SCLC as well
as tumour progression and metastases formation in SCC of the
lung. Whereas in SCLC the histological diagnosis is generally
predictive for the clinical course, which is characterized by exten-
sive metastases formation, the histomorphological criteria of
malignancy of NSCLC are far less reliable for the assessment of
the clinical outcome than tumour staging (Nesbitt et al, 1995).
Allelotype studies ofNSCLC indicated loss ofgenetic material on
chromosome 10q in up to 27% ofcases (Tsuchiya etal, 1992; Satoet
al, 1994), whichcorrelates well withtheoverall percentage of23% of
LOH in the three subgroups of NSCLC in our study. Although one
allelotype study showedahigherincidence ofdeletioninSCCthanin
adenocarcinomas, it failed to establish a significant correlation
between LOH on chromosome 10q and clinicopathological parame-
ters. This is probably because ofthe fact that a single RFLP marker
was investigated per chromosomal arm, which reduced the number
of informative cases per tumour subgroup. In addition, stage IV
tumours wereexcluded fromthe statistical analysis (Sato etal, 1994).
We detected deletions preferentially in metastatic stage IV SCC,
whereas non-metastatic SCC carried deletions only sporadically. The
factthat wefailed toidentify deletions inadenocarcinomas andlarge-
cell carcinomas isprobably because ofthe limited numberofcases.
To test the predictive value of chromosome 10q deletions, we
asked for the clinical history of those three patients with pMO
tumours that showed LOH. Although the period of time after
surgery amounted to a maximum of 1 year, this was very informa-
tive in two cases. One patient (case 42) was reported to have
undergone surgery because of a lung tumour 3 years before
removal of the tumour investigated. As the second tumour was
located in theperiphery ofthe lung without bronchial relationship,
it is likely that it evolved as a metastatic clone of the first
neoplasm. Another patient (case no. 44) died 2 months after
surgery with clinical evidence of brain metastases and local
tumour recurrence. These clinical findings support the statistical
data that chromosome 10q loss is associated with tumour progres-
sion and metastases formation. It is interesting to note that the
single SCLC without metastasis formation (case no. 1) did not
show an allelic loss. However, the significance of this association
has to be tested by additional cases of non-metastatic SCLC,
which are difficult to ascertain.
The fact that some metastatic tumours did not show LOH is
related to the limited number of polymorphisms investigated so
far. The percentage ofcases with LOH will probably increase with
the number of additional markers and metastatic SCC may be of
particular interestforthe future refinement ofthe candidate region.
We observed a high incidence of allelic loss in the region
between the markers D1OS677 and DIOS1223, which seems to
harbour at least one tumour-suppressor gene. Although two non-
overlapping regions between the loci DIOS677/DlOS1237 and
DIOS1213/DlOS1223 could be identified, the exact location and
refinement of the minimal regions will need more markers and a
larger sample size.
A similar result was found by a deletion mapping study of glial
brain tumours: two gliomas showed interstital deletions that were
located centromerically and were bracketed by the loci DIOS109
and DIOS206, whereas the majority carried deletions covering the
distal part of the chromosome arm, with a non-overlapping region
between the marker DIOS587 and DIOS216 (Rasheed et al, 1995).
These regions co-localize with the ones that we defined and are
approximately mapped to chromosome bands lOq22 and lOq25.
The comparison between the deletion pattems ofgliomas and those
of lung carcinomas is intriguing. Similar to glioblastomas, SCLC
generally exhibit deletions of the entire chromosome or chromo-
somal arm (Levin et al, 1994; Ried et al, 1994; Petersen et al,
1997a), whereas SCC and astrocytoma are more frequently charac-
terized by interstitial deletions (Rasheed et al, 1995). Both, astrocy-
toma and SCC may progress to glioblastoma and SCLC
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respectively (Churg et al, 1980; Kleihues et al, 1995). Hypo theti-
cally, the morphological and biological transition to the aggressive
phenotype is mediated by a genetic alteration ofchromosome lOq.
As shown in Table 2 the MXI1 gene has been mapped to the
chromosomal band lOq24-q25 and is thus located centromerically
to the markers DIOS169 and D1OS212. Although the physical and
genetic distances ofthe adjacent markers to MXI1 are unknown, it
is likely that the second region of LOH between the markers
DIOS1223 and DIOS1213 coincides with the locus of the MXII
gene. We failed to identify the mutations in two hotspot regions as
reported in prostate cancer (Eagle et al, 1995). The significance of
this putative tumour-suppressor gene is unclear. To our knowl-
edge, there are no further reports of mutations, and others have
failed to confirm the findings in prostate cancer (Gray et al, 1995).
Very recently, a new tumour-suppressor gene has been identi-
fied on chromosome lOq23, which was termed PTEN and
MMAC1 by two groups who discovered the gene almost simulta-
neously (Li et al, 1997; Steck et al, 1997). As it is mutated in
advanced gliomas, breast and prostate carcinomas, it is an impor-
tant candidate gene for late-stage lung carcinomas. In general, the
functional role of angiogenesis inhibitor genes, which have been
implicated in tumour progression and metastasis formation, is also
consistent with the concept that a deletion is associated with the
metastatic phenotype (Hanahan and Folkman, 1996).
In summary, our data indicate that chromosome lOq harbours at
least one tumour-suppressor gene that is associated with advanced
tumour stage and metastastic phenotype in pulmonary SCC and
SCLC. The usefulness ofthis lesion as a genetic marker for tumour
progression and clinical outcome will be tested by future prospec-
tive studies. Hopefully, itwillhelp clinicians andpathologists in the
assessment ofthe malignant potential ofhuman lung cancer.
ABBREVIATIONS
CGH, comparative genomic hybridization; LOH, loss of hetero-
zygosity; MMAC1, mutated in multiple advanced cancers; MXI1,
MAX interacting protein; NSCLC, non-small-cell lung carcinoma;
SCLC, small-cell lung carcinoma; SCC, squamous cell carcinoma
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